CSL

CSL's Seqirus caps off $156M expansion of flu manufacturing facility in Raleigh suburb
Endpoints
Thu, 06/9/22 - 10:23 am
CSL
Seqirus
drug manufacturing
North Carolina
The top 10 biopharma M&A deals in 2021
Fierce Pharma
Tue, 01/18/22 - 10:53 am
M&A
CSL
Vifor
Jazz Pharmaeuticals
GW Pharma
Novo Nordisk
Dicerna
Horizon Therapeutics
Viela Bio
Perrigo
HRA Pharma
Sanofi
Kadmon
Merck
Acceleron
Pfizer
Arena Pharmaceuticals
Translate Bio
Trillium Therapeutics
Amgen
Five Prime Therapeutics
Days after buyout news, Vifor outlines plan to offload 'non-core' finished drug manufacturing wing
Endpoints
Thu, 12/16/21 - 11:53 pm
Vifor Pharma
CSL
M&A
Biopharma’s buyout year ends with a bang
EP Vantage
Wed, 12/15/21 - 10:37 am
M&A
CSL
Vifor Pharma
Pfizer
Arena Pharmaceuticals
As year-end deals start to sizzle, CSL moves a biotech buyout to the front burner with deal expected Tuesday — report
Endpoints
Mon, 12/13/21 - 11:02 am
M&A
Vifor Pharma
CSL
Takeda, CSL hereditary angioedema meds need steep discounts following real-world evidence review, ICER says
Fierce Pharma
Wed, 08/25/21 - 09:32 pm
Takeda
CSL
hereditary angiodema
HAE
RWE
Takhzyro
Cinryze
Haegarda
UniQure/CSL hit by FDA clinical hold for hem B gene therapy program after liver cancer find
Fierce Biotech
Mon, 12/21/20 - 11:09 am
uniQure
CSL
FDA
clinical trials
hemophilia B
gene therapy
etranacogene dezaparvovec
Pharvaris lands another $80M as it looks to tackle Takeda and CSL with an oral approach for HAE
Endpoints
Wed, 11/18/20 - 11:07 pm
Pharvaris
HAE
Takeda
CSL
Key trial test begins for plasma-based COVID-19 therapy from Takeda, CSL
BioPharma Dive
Sat, 10/10/20 - 11:27 pm
clinical trials
plasma
COVID-19
Takeda
CSL
UniQure out-licenses hemophilia B gene therapy in deal valued up to ~$2.1B
Seeking Alpha
Wed, 06/24/20 - 11:29 pm
uniQure
CSL
hemophilia B
etranacogene dezaparvovec
Takeda, CSL forge coronavirus alliance, forgoing their own drugs in the process
BioPharma Dive
Wed, 04/8/20 - 10:33 am
Takeda
CSL
COVID-19
plasma
drug development
Want to win over payers, pharma? Forget the 'me-too' drugs, CSL chief says
Fierce Pharma
Tue, 01/15/19 - 11:06 am
CSL
Paul Perreault
me-too drugs
payers
Shire scores new FDA thumbs-up for HAE drug Cinryze in latest bid to fend off rival CSL
Fierce Pharma
Thu, 06/21/18 - 12:02 pm
CSL
HAE
Shire
Cinryze
Haegarda
CSL revamps branding to recruit employees, partners
Fierce Pharma
Mon, 03/5/18 - 03:01 pm
CSL
branding
CSL snags a preclinical stem cell therapy in $416M Calimmune buyout
Endpoints
Mon, 08/28/17 - 09:29 am
CSL
Calimmune
M&A
stem cells
FDA OKs CSL’s new HAE drug, already embroiled in a blockbuster fight with Shire
Endpoints
Fri, 06/23/17 - 09:48 am
FDA
CSL
HAE
hereditary angiodema
Shire
Haegarda
Firazyr
Kalbito
Shire, armed with new rare disease patent, aims to block CSL's Haegarda launch
Fierce Pharma
Mon, 04/17/17 - 04:10 pm
Shire
rare disease
CSL
patents
Haegarda
HAE
hereditary angiodema
Hemophilia marketing tactics raise questions as market heats up
Fierce Pharma
Thu, 01/14/16 - 08:47 pm
hemophilia
drug marketing
Biogen
CSL
Bayer
Roche
First flu vaccine with immune-boosting adjuvant approved for US market
Stat
Wed, 11/25/15 - 11:35 am
flu vaccines
vaccines
immune-boosting adjuvants
Fluad
CSL
Novartis
Seqirus
How Does Novavax Compare to Its Competitors?
Yahoo/Market Realist
Mon, 08/31/15 - 11:18 am
Novavax
Inovio
iBio
CSL
Sinovac
Biota

Pages